AAU

0.006

20%

MHK

0.185

-50%

FBR

0.006

20%

XPN

0.008

-27.3%

JGH

0.045

18.4%

CHM

0.003

-25%

RKB

0.013

18.2%

MEM

0.003

-25%

PGD

0.31

17%

3DP

0.047

-17.5%

BDG

0.08

14.3%

BNL

0.005

-16.7%

PIM

0.062

12.7%

CTT

0.285

-16.2%

ADX

0.027

12.5%

CRN

0.192

-12.7%

REE

0.019

11.8%

USL

0.382

-11.2%

ART

0.345

11.3%

BPT

1.152

-10.7%

CPM

0.05

11.1%

BSA

0.125

-10.7%

1CG

0.011

10%

JNS

0.135

-10%

8CO

0.022

10%

RAU

0.18

-10%

KGL

0.11

10%

LRD

0.028

-9.7%

AS2

0.012

9.1%

IPD

0.047

-9.6%

DRE

0.012

9.1%

MVP

0.62

-9.5%

RHY

0.061

8.9%

RWL

0.19

-9.5%

MEG

0.04

8.1%

LIT

0.01

-9.1%

DRO

3.42

7.9%

NVO

0.1

-9.1%

C1X

0.07

7.7%

PEC

0.021

-8.7%

Arovella Therapeutics (ASX:ALA): A novel cell therapy treatment for cancers and tumours

Published on Monday September 2 2024

YouTube Video VVVFRVZOQ01GU1J4RmEwQmIyd0tMUzBnLlU5bjhWQkxiazFj

Ahead of appearing at the Spark+ Australian Equities Day in Singapore, Arovella’s (ASX:ALA) CEO & Managing Director Dr Michael Baker speaks with The Stock Network’s Lel Smits about:

🩸 The current lead product coming out of Arovella Therapeutics’ cell therapy platform – ALA-101 – iNKT cells create receptors that target antigens
🩸 How ALA-101 targets cancers and tumours
🩸 Timing of Phase 1 trials for ALA-101

Watch the full interview ⚡️ https://youtu.be/Hb_HZmKYCNA
Register to attend Australian Equities Day: https://www.eventbrite.sg/e/spark-plus-australian-equities-day-tickets-939180011697